High mobility group B1 protein interacts with its receptor RAGE in tumor cells but not in normal tissues

Oncology Letters

Volumn 3, Issue 1, 2012, Pages 214-218

  Todorova, Jordanas ^a   Pasheva, Evdokia ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY   (Bulgaria)

Author keywords

HMGB1 protein; RAGE; Subcellular localization; Tumorigenesis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; HIGH MOBILITY GROUP B1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GUERIN TUMOR; IMMUNOBLOTTING; IMMUNOPRECIPITATION; KIDNEY; LIVER; LUNG; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RAT; SPLEEN; TESTIS; TUMOR CELL;

EID: 84855238144     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.459     Document Type: Article

References (35)

1. Thomas JO and Travers A: HMG1 and 2, and related 'architectural' DNA-binding proteins. Trends Biochem Science 26: 167-174, 2001.
2. Bianchi ME, Bertrame M and Paonessa G: Specific recognition of cruciform DNA by nuclear protein HMG1. Science 243: 1056-1059, 1989.
3. Pil PM and Lippard SJ: Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science 256: 234-237, 1992.
4. Pasheva EA, Pashev IG and Favre A: Preferential binding of high mobility group 1 protein to UV-damaged DNA. Role of the COOH-terminal domain. J Biol Chem 273: 24730-24736, 1998.
5. Paull T, Hakynson MJ and Johnson RC: The nonspecific DNA-binding and bending proteins HMG1 and HMG2 promote the assembly of complex nucleoprotein structures. Genes Dev 7: 1521-1534, 1993.
6. Onate SA, Prendergast P, Wagner JP, Nissen M, Reeves R, Pettijhon DE and Edwards DP: The DNA-bending protein HMG-1 enhances progesterone receptor binding to its target DNA sequences. Mol Cell Biol 14: 3375-3391, 1994.
7. Ugrinova I, Zlateva S, Pashev IG and Pasheva EA: Native HMGB1 protein inhibits repair of cisplatin-damaged nucleosomes in vitro. Int J Biochem Cell Biol 41: 1556-1562, 2009.
8. Topalova D, Ugrinova I, Pashev IG and Pasheva EA: HMGB1 protein inhibits DNA replication in vitro: a role of the acetylation and the acidic tail. Int J Biochem Cell Biol 40: 1536-1542, 2008.
9. Bonaldi T, Langst G, Strohner R, Becker PB and Bianchi ME: The DNA chaperone HMGB1 facilitates ACF/CHRAC dependent nucleosome sliding. EMBO J 21: 6865-6873, 2002.
10. Ugrinova I, Pashev IG and Pasheva EA: Nucleosome binding properties and co-remodeling activities of native and in vivo acetylated HMGB-1 and HMGB-2 proteins. Biochemistry 48: 6502-6507, 2009.
11. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A and Tracey KJ: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251, 1999.
12. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H and Tracey KJ: High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192: 565-570, 2000.
13. Degryse B and De Virgilio M: The nuclear protein HMGB1, a new kind of chemokine. FEBS Lett 553: 11-17, 2003.
14. Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195, 2002.
15. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, Rubartelli A, Agresti A and Bianchi ME: Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22: 5551-5560, 2003.
16. Youn JH and Shin JS: Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J Immunol 177: 7889-7897, 2006.
17. Ito I, Fukuzawa J and Yoshida M: Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J Biol Chem 282: 16336-16344, 2007.
18. Ditsworth D, Zong WX and Thompson CB: Activation of poly(ADP)-ribosepolymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus. J Biol Chem 282: 17845-17854, 2007.
19. Ellerman JE, Brown CK, De Vera M, Zeh HJ, Billiar T, Rubartelli A and Lotze M: Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 13: 2836-2848, 2007.
20. Sasahira T, Kirita T, Oue N, Bhawal UK, Yamamoto K, Fujii K, Ohmori H, Luo Y, Yasui W, Bosserhoff AK and Kuniyasu H: High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci 99: 1806-1812, 2008.
21. Fages C, Nolo R, Huttunen H, Eskelinen E and Rauvala H: Regulation of cell migration by amphoterin. J Cell Science 113: 611-620, 2000.
22. Taguchi A, Blood DC, Del Toro G, Canet A, Lee D.C, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM and Schmidt AM: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405: 354-360, 2000.
23. Kuniyasu H, Chihara Y and Takahashi T: Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 10: 445-448, 2003.
24. Bierhaus A, Humpert P, Morcos M, Wendt T, Chavakis T, Arnold B, Stern D and Nawroth P: Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83: 876-886, 2005.
25. Sasahira T, Akama Y, Fujii K and Kuniyasu H: Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch 446: 411-415, 2005.
26. Kostova N, Zlateva S, Ugrinova I and Pasheva E: The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem 337: 251-258, 2010.
27. Dignam JD: Preparation of extracts from higher eukaryotes. Methods Enzymol 182: 194-203, 1990.
28. Prasad S and Thakur MK: Distribution of high mobility group proteins in different tissues of rats during aging. Biochem Int 20: 687-695, 1990.
29. Muller S, Ronfani L and Bianchi M: Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Int Med 255: 332-343, 2004.
30. Flohr A, Rogalla P, Meiboom M, Borrmann L, Krohn M, Thode-Halle B and Bullrdiek J: Variation of HMGB1 expression in breast cancer. Anticancer Res 21: 3881-3885, 2001.
31. Bartling B, Hofmann H, Weiglel B, Silber S and Simm A: Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 26: 293-301, 2005.
32. Merenmies J, Pihlaskari R, Laitinen J, Wartiovaarall J and Rauvala H: 30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth. J Biol Chem 266: 16722-16729, 1991.
33. Sparvero L, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, Rutledge R, Lin B, Amoscato A, Zeh H and Lotze M: RAGE (Receptor for Advanced Glycation End products), RAGE ligands and their role in cancer and inflammation. J Transl Med 7: 17-39, 2009.
34. Rouhiainen A, Imai S, Rauvala H and Parkkinen J: Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb Haemost 84: 1087-1094, 2000.
35. Passalacqua M, Zicca A, Sparatore B, Patrone M, Melloni E and Pontremoli S: Secretion and binding of HMG1 protein to the external surface of the membrane are required for murine erythroleukemia cell differentiation. FEBS Lett 400: 275-279, 1997.